Pharmaceutical

First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico

BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the…

11 months ago

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of…

11 months ago

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

LA JOLLA, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market…

11 months ago

Samsung Bioepis Releases First Quarter 2024 US Biosimilar Market Report

Report highlights latest biosimilar pricing and market share status, including state of the adalimumab marketBiosimilar Deep Dive section illustrates patient…

11 months ago

Vision Sensing Acquisition Corp. Announces Definitive Agreement and Plan of Merger with Mediforum Co., Ltd

The Combined Company Is Expected To Trade On Nasdaq Post-Closing Under A New Ticker SymbolMediforum is a leading biotechnology company…

11 months ago

Arvinas Appoints Jared Freedberg as General Counsel

Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4)NEW HAVEN, Conn., Jan. 16, 2024 (GLOBE NEWSWIRE)…

11 months ago

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company…

11 months ago

PrestoDoctor Expands Its Cannabis Telemedicine Service to West Virginia

MESQUITE, NV / ACCESSWIRE / January 17, 2024 / Cannabis Sativa, Inc. (OTCQB:CBDS) announces that PrestoDoctor - the #1 patient-rated…

11 months ago

Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS

Further Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)Market opportunity estimated to be greater than US$1…

11 months ago